Chimerix raises $45M for conjugated antivirals
This article was originally published in Scrip
Executive Summary
Chimerix, based in Durham North Carolina, has raised $45 million in a series F financing round to further the clinical- development of its novel antivirals,. The company's lead candidate, CMX001, is in Phase II trials in immunocompromised transplant and cancer patients to treat cytomegalovirus infection (CMV) and adenovirus, and for potential use as a medical countermeasure in the event of a smallpox release (with government contracts). Chimerix also has CMX157, a potent nucleoside analogue against multi-drug resistant HIV infections, which is in Phase I studies.